Dongfang Baitai attended the Qianhai Fund-of-Funds Private Equity Investment Summit and Partner Conference.
[Summary Description]
On April 25, 2019, Qianhai Mother Fund hosted the “Focusing on the STAR Market, Fostering New Growth Drivers” Henan Private Equity Investment Summit and the 2018 Annual Partners’ Conference at the Sofitel International Hotel in Zhengzhou. Bai Yi, General Manager of Dongfang Baitai, attended the event by invitation and was awarded the Best Performance Prize in the Best Investment Case category.
On April 25, 2019, Qianhai Mother Fund solemnly hosted the “Focusing on the STAR Market and Fostering New Growth Drivers” — Henan Province Private Equity Investment Summit Forum and the 2018 Annual Partners’ Conference at the Sofitel International Hotel in Zhengzhou. Bai Yi, General Manager of Oriental Baitai, attended the event by invitation and was awarded the Best Performance Prize under the Best Investment Case category.
Qianhai Equity Investment Fund (Limited Partnership), commonly known as the “Qianhai Fund of Funds,” is a large-scale, commercially‑oriented private equity fund of funds established in December 2015 in Qianhai, Shenzhen. With a total size of RMB 28.5 billion, it is currently the largest commercially‑raised fund of funds in China and a leading private equity investment fund.

Beijing Dongfang Baitai Biotechnology Co., Ltd. is a leading enterprise in China’s biopharmaceutical sector. Founded in 2011 and located in the Yizhuang Economic-Technological Development Area, it is an innovative high-tech company engaged in the research, development, and production of antibody drugs, focusing on new therapeutic and preventive biopharmaceutical products for major diseases.
The company has established an industrialization technology platform of world‑class caliber, centered on innovative antibody therapeutics and next‑generation therapeutic vaccines, and spanning the entire R&D and manufacturing process. Its product portfolio addresses a wide range of prevalent diseases, including malignant tumors, diabetes, rheumatoid arthritis, psoriasis, and hyperlipidemia. Product categories encompass fully human monoclonal antibodies, humanized monoclonal antibodies, bispecific antibodies, antibody fusion proteins, antibody–drug conjugates, and therapeutic vaccines. Currently, six candidates have entered clinical development, while twelve are at various preclinical stages.

In 2017, Qianhai Equity Investment Fund invested in Orient Biotech. Over the past two years, the company has steadily grown and expanded, continuously strengthening its development of innovative antibody‑drug technologies, enriching its R&D pipeline, refining its product portfolio, accelerating clinical trial progress, and expediting the construction of its antibody‑drug R&D and manufacturing base. Among Qianhai Equity Investment Fund’s many portfolio companies, Orient Biotech stood out and was awarded the Best Performance Prize in the Best Investment Case category.

“Focusing on the STAR Market and Fostering New Growth Drivers” — the Henan Provincial Private Equity Investment Summit Forum was co-hosted by the Henan Provincial Development and Reform Commission, the Henan Provincial Local Financial Supervision Administration, Qianhai Fund of Funds, and the Zhongyuan Qianhai Equity Investment Fund. The forum brought together over 300 participants, including Comrade Zhu Huanran, Secretary-General of the Henan Provincial People’s Government; senior officials from the Henan Provincial Development and Reform Commission, the Local Financial Supervision Administration, and the Securities Regulatory Bureau; investors from Qianhai Fund of Funds and Zhongyuan Qianhai Equity Investment Fund; experts from the Shanghai Stock Exchange’s Registration and Review Center; partners of renowned domestic private equity funds; leading entrepreneurs from sectors such as 5G, healthcare, and intelligent manufacturing; industry specialists; representatives from relevant investment‑financing platforms under the Henan Provincial Government and various municipal governments; as well as executives from provincial financial institutions, listed companies, and pre‑IPO enterprises.

At the forum, Comrade Zhu Huanran, Secretary-General of the Henan Provincial Government, and Mr. Jin Haitao, Chief Executive Partner of Qianhai Fund, each delivered remarks. Bai Yi, General Manager of Oriental Baitai, was invited as a biopharmaceutical industry expert to participate in the roundtable discussion on “Trends in the Healthcare Industry and Investment Opportunities,” where he joined numerous leaders, experts, investors, and entrepreneurs from the healthcare sector to discuss the industry’s development trends and investment prospects.

Health is a perennial concern for humanity. Over the past two years, amid intensive policy reforms and volatile capital market conditions, China’s healthcare sector has embarked on a new phase of development. Since the 2017 national medical insurance negotiations, bolstered by the outcomes of those talks and robust sales performance, virtually all pharmaceutical companies have come to recognize that early inclusion in the national reimbursement scheme offers significant advantages for most innovative drugs. With the 2019 revision of the national reimbursement drug list imminent, General Manager Bai Yi drew on his industry experience to share insights with attendees on key issues—such as identifying core priorities, substantiating product value, and preparing adequately for the process. He also discussed the implications of the recently introduced “4+7” volume‑based procurement policy and outlined strategic responses that companies should adopt.
Participants from policy, industry, hospital networks, and investment sectors jointly interpreted and discussed the latest policies and regulations, explored the opportunities and challenges facing the industry, and identified innovative approaches to drive its development, thereby helping all stakeholders build a sustainable, shared health ecosystem.

Concurrently with the summit forum, the Qianhai Private Equity Fund (Limited Partnership) held its 2018 Annual Partners’ Meeting. At this meeting, the “2018 Annual Operating Report of the Qianhai Private Equity Fund (Limited Partnership)” was reviewed; the “Qianhai Private Equity Fund (Limited Partnership) First-Quarter 2019 Investment Brief” was presented; and the “Proposal on Establishing the Second-term Advisory Committee and Electing Its Chairperson” was deliberated, among other items.
At present, biotechnology‑based drugs are a major focus and priority in global pharmaceutical R&D. With years of experience in developing antibody therapeutics, Dongfang Baitai is committed to continuously strengthening the development of innovative biopharmaceuticals, striving to become a leading large‑scale pharmaceutical company in China. The company is dedicated to enhancing the market share and competitiveness of Chinese antibody drugs on the international stage, and to building itself into a globally recognized innovator in the biopharmaceutical sector.
A warm welcome to Vice Mayor Lin Keqing for his visit and guidance at Dongfang Baitai.
On October 24, 2016, Beijing Vice Mayor Lin Keqing and his delegation visited Beijing Dongfang Baitai Biotechnology Co., Ltd. and Baitai Bio-pharmaceutical Co., Ltd., conducted an in-depth review of the companies’ R&D progress, inspected the production workshops on-site, and engaged in cordial discussions.
Leave a Message Online Online Message